DVAX
DYNAVAX TECHNOLOGIES CORPNo price
Insider net
$0
no open-market trades · since Feb 10
New fund stakes
0
Q1 2026 13F · 21 exits
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Feb 10. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q1 2026: 0 added (0 new), 21 trimmed or exited.
Who's buying
13F· Q1 20260
new positions
21
exits
| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | EXIT | $0.00 |
| STATE STREET CORP | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | $0.00 |
| Invesco Ltd. | EXIT | $0.00 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | $0.00 |
| SOROS FUND MANAGEMENT LLC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Dec 2025Recent actions
| Date | Firm | Rating |
|---|---|---|
| Dec 24, 2025 | William Blair DOWNGRADE | Market Perform |
| Aug 22, 2025 | JMP Securities REITERATE | Market Outperform |
| Aug 8, 2025 | JMP Securities MAINTAIN | Market Outperform |
| May 7, 2025 | JMP Securities MAINTAIN | Market Outperform |
| Apr 17, 2025 | Goldman Sachs MAINTAIN | Sell |
| Feb 21, 2025 | Citizens Capital Markets MAINTAIN | Market Outperform |
Insider ledger
Form 4$0
open-market buys or sells · since Feb 10
| Insider | Type | Value |
|---|---|---|
Spencer Ryan CEO and Director Feb 10, 2026 | TO ISSUER | 130,000 sh |
SILVERNAIL LAUREN P Director Feb 10, 2026 | TO ISSUER | 7,125 sh |
Myers Scott Dunseth Director Feb 10, 2026 | TO ISSUER | 31,204 sh |
Myers Scott Dunseth Director Feb 10, 2026 | TENDER | 3,800 sh |
MacDonald Kelly SVP and CFO Feb 10, 2026 | TO ISSUER | 100,000 sh |
MacDonald Kelly SVP and CFO Feb 10, 2026 | TO ISSUER | 65,000 sh |
MacDonald Kelly SVP and CFO Feb 10, 2026 | TO ISSUER | 70,000 sh |
MacDonald Kelly SVP and CFO Feb 10, 2026 | TO ISSUER | 28,283 sh |
Washington
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 8, 2026 Clinical trial readout
T-90d Trial Readout: rF1V-1018 (Phase 2)
Trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Mar 31, 2026 Inst.
BlackRock, Inc. · EXIT
0 shares ($0.00)
Mar 31, 2026 Inst.
STATE STREET CORP · EXIT
0 shares ($0.00)
Feb 10, 2026 Insider
Spencer Ryan disposed of 130,000 shares
CEO and Director
Feb 10, 2026 Insider
SILVERNAIL LAUREN P disposed of 7,125 shares
Director
Feb 10, 2026 Insider
Myers Scott Dunseth disposed of 31,204 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 8, 2026
Trial readout
T-90d Trial Readout: rF1V-1018 (Phase 2)
Trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age Sponsor: Dynavax Technologies Corporation…
Nov 3, 2026
Earnings date
DVAX Q3 2026 Earnings Scheduled · 2026-11-03
Nov 1, 2026
Trial readout
T-90d Trial Readout: rF1V-1018 (Phase 2)
Trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age Sponsor: Dynavax Technologies Corporation…
Oct 30, 2026
Trial readout
T-90d Trial Readout: rF1V-1018 (Phase 2)
Trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age Sponsor: Dynavax Technologies Corporation…
Aug 5, 2026
Earnings date
DVAX Q2 2026 Earnings Scheduled, 2026-08-05